As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

University of California Davis School of Medicine, Sacramento, CA.

B cell acute lymphoblastic leukemia (B ALL) is the most common childhood malignancy with more than ninety percent cure rates and current research efforts are directed towards development of curative ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted conditional marketing ...

BREVARD COUNTY, FLORIDA – Sunday, April 27, 2025, at 1 p.m., the American Legion Post 200, 105 Ocean Blvd., Satellite Beach, ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

12, 2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Obe-cel is under regulatory review in both the EU and the U.K., and the Company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

B细胞急性淋巴细胞白血病是一种常见的儿童癌症，并且有越来越多的研究表明该病的发病率与遗传有关。目前发现与白血病发病相关的基因多与淋巴细胞分化、细胞周期和细胞凋亡信号传导有关，DNA损伤则与髓系白血病的发病机制有关。DNA修复基因的变异会导致在DNA双 ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to ...